tiprankstipranks
Trending News
More News >
Saniona AB (SE:SANION)
:SANION

Saniona AB (SANION) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Saniona AB

(Frankfurt:SANION)

Rating:77Outperform
Price Target:
kr10.50
▲(14.13%Upside)
Saniona AB's stock is rated highly due to strong financial performance and technical indicators. The financial recovery and low P/E ratio contribute to a favorable valuation. However, caution is warranted due to potential technical pullbacks.

Saniona AB (SANION) vs. iShares MSCI Sweden ETF (EWD)

Saniona AB Business Overview & Revenue Model

Company DescriptionSaniona AB is a Swedish biopharmaceutical company focused on developing treatments for central nervous system disorders, eating disorders, and rare diseases. The company's research is centered around ion channel drug discovery, leveraging its expertise to identify and advance novel therapeutic candidates. Saniona's core products include proprietary compounds in various stages of clinical development, intended to address unmet medical needs across its target sectors.
How the Company Makes MoneySaniona makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue streams include proceeds from partnerships and collaborations with other pharmaceutical firms, which may involve milestone payments and royalties from successful product commercialization. Saniona also receives funding through research grants and public offerings to support its ongoing research and development activities. Additionally, the company may earn income from out-licensing its proprietary compounds or technology platforms to other entities in the pharmaceutical industry.

Saniona AB Financial Statement Overview

Summary
Saniona AB has shown a solid financial recovery and growth trajectory, with significant improvements across all financial statement metrics. The transition from a loss-making position to profitability, enhanced financial stability, and optimized cash flows are positive indicators. The strong balance sheet and cash flow position provide a cushion against potential volatility in the biotechnology industry.
Income Statement
65
Positive
Saniona AB has demonstrated impressive revenue growth, increasing from SEK 16.84M in 2023 to SEK 334.67M in 2024, showcasing a strong market traction in the biotechnology space. The gross profit margin improved significantly to 98.5% in 2024 from 69.9% in 2023, reflecting efficient cost management. Additionally, the net profit margin turned positive to 56.4% in 2024, indicating profitability after years of losses. However, the EBIT and EBITDA margins are high at 72.3% and 76.1%, respectively, showing robust operating performance.
Balance Sheet
72
Positive
The company's balance sheet shows strong financial stability, with a positive shift in stockholders' equity from negative SEK 21.94M in 2023 to positive SEK 231.82M in 2024. The debt-to-equity ratio decreased significantly to 0.05, underscoring a low leverage position which reduces financial risk. The equity ratio improved to 68.2%, highlighting a solid capital structure. This healthy financial position suggests reduced risk and potential for future growth.
Cash Flow
78
Positive
Saniona AB's cash flow statements reflect a remarkable turnaround. The free cash flow increased from negative SEK 85.66M in 2023 to positive SEK 249.07M in 2024, signaling strong cash generation capabilities. The operating cash flow to net income ratio is 1.32, indicating efficient cash management in relation to profits. Moreover, the free cash flow to net income ratio is 1.32, suggesting a healthy conversion of earnings into cash.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
334.67M16.84M15.28M10.48M8.20M
Gross Profit
329.58M11.78M10.81M5.85M4.95M
EBIT
241.88M-81.06M-225.72M-411.57M-159.38M
EBITDA
251.90M-68.28M-196.00M-398.86M-64.64M
Net Income Common Stockholders
188.71M-95.81M-245.36M-410.90M-73.43M
Balance SheetCash, Cash Equivalents and Short-Term Investments
303.26M30.96M111.71M356.86M573.87M
Total Assets
339.73M64.14M153.70M440.25M692.18M
Total Debt
10.50M71.41M81.52M99.77M47.51M
Net Debt
-292.75M40.45M-30.18M-257.08M-526.36M
Total Liabilities
107.92M86.08M100.99M158.25M88.72M
Stockholders Equity
231.82M-21.94M52.71M282.00M603.46M
Cash FlowFree Cash Flow
249.07M-85.66M-282.52M-346.52M-179.71M
Operating Cash Flow
249.20M-85.53M-281.54M-345.04M-174.71M
Investing Cash Flow
-124.00K-129.00K6.84M43.16M99.51M
Financing Cash Flow
23.25M-7.97M-20.52M50.60M621.18M

Saniona AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price9.20
Price Trends
50DMA
7.44
Positive
100DMA
7.40
Positive
200DMA
6.27
Positive
Market Momentum
MACD
0.47
Negative
RSI
64.70
Neutral
STOCH
86.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Positive. The current price of 9.2 is above the 20-day moving average (MA) of 8.51, above the 50-day MA of 7.44, and above the 200-day MA of 6.27, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 64.70 is Neutral, neither overbought nor oversold. The STOCH value of 86.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SANION.

Saniona AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
kr1.26B4.81152.78%1533.99%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
48
Neutral
kr917.45M-48.22%67.70%
48
Neutral
kr379.37M-47.73%45.52%93.35%
47
Neutral
kr1.16B-42.24%-19.44%
41
Neutral
kr367.75M-194.31%1643.36%50.36%
32
Underperform
kr375.12M-205.65%24.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SANION
Saniona AB
9.30
6.05
185.71%
SE:GUARD
Guard Therapeutics International AB
18.60
-15.54
-45.52%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
7.09
-6.86
-49.18%
SE:XBRANE
Xbrane Biopharma AB
0.25
-0.06
-19.81%
SE:XSPRAY
Xspray Pharma AB
31.30
-42.81
-57.77%
SE:SYNACT
SynAct Pharma AB
18.72
11.78
169.90%

Saniona AB Corporate Events

Saniona AB Annual Shareholders’ Meeting: Key Resolutions and Strategic Initiatives
May 28, 2025

Saniona AB held its annual shareholders’ meeting on May 28, 2025, where several key resolutions were adopted. The meeting approved the financial statements for 2024, decided against issuing dividends, and re-elected board members with new appointments in leadership roles. Additionally, the meeting authorized the board to issue new shares and adopted an employee option program, reflecting strategic moves to strengthen the company’s financial position and incentivize its workforce.

Saniona AB Reports Strong Q1 2025 with Key Developments
May 28, 2025

Saniona AB reported a strong start to 2025, with significant financial and operational milestones achieved in the first quarter. The company secured seed funding for its joint venture, advanced regulatory processes for tesofensine, and initiated manufacturing and toxicology studies for SAN2355. Additionally, Saniona extended its collaboration with Boehringer Ingelheim and completed a successful TO4 financing, strengthening its financial position and setting the stage for continued growth.

Saniona Appoints New CFO to Strengthen Financial Strategy
May 12, 2025

Saniona has appointed Johnny Stilou as Chief Financial Officer, bringing over 25 years of financial leadership experience to the company. His expertise in corporate finance and capital markets is expected to support Saniona’s financial strategy and investor relations as it advances its pipeline and seeks long-term financing solutions.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.